With eye on Heron's ri­val prod­uct, Paci­ra to buy MyoScience to for­ti­fy its Ex­par­el fran­chise

As Paci­ra braces it­self ahead of the FDA de­ci­sion of Heron Ther­a­peu­tics’ ri­val non-opi­oid treat­ment, the com­pa­ny is beef­ing up its pain man­age­ment fran­chise, by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.